Making the “unsampleable sampleable” – closing the gap
in respiratory disease diagnostics with breath sampling
The need
-
Global health threat: respiratory infections including tuberculosis and pneumonia are among the leading causes of death globally, causing around 4 million deaths annually¹ ​​​
​​
-
Challenge: rapid and accurate identification of the pathogen causing the infection is essential to guide treatment and reduce antibiotic overuse
​​
-
Current limitations: shortcomings of existing sampling methods pose a major barrier to testing. Samples from the lower respiratory tract are hard to obtain, invasive, unreliable, or undesirable
​​
-
Innovation needed: experts see breath sampling as a promising, non-invasive solution to close the diagnostic gap
Our solution: AveloMask - a breath aerosol collector
-
Our breath sampling kit contains a special mask and buffer tube, and works with existing molecular tests​
​​​
-
Non-invasive and easy to use – anywhere, anytime
​​
-
The filter inside the mask captures disease-causing viruses and bacteria from the entire respiratory tract
​​
-
After use, the filter can be quickly and easily transferred into the buffer tube for molecular testing
1. Collect
Wear for 30 minutes
2. Elute
Transfer to
lab tube with pathogen stabilizing buffer
3. Test and Treat
Diagnose & treat multiple diseases
The impact
-
Saving lives: better diagnosis for earlier and tailored antibiotic or antiviral treatment​
​​
-
Expanding access: AveloMask enables diagnosis for up to 50% of patients who cannot be reached by existing sampling methods² – in any care setting, from the hospital to the field
​​
-
Fighting antimicrobial resistance (AMR): AveloMask works with existing respiratory multiplex tests which differentiate between viral and bacterial infections to reduce the more than 65% unnecessarily prescribed antibiotics in primary care³
​​
-
Making every breath count: establish breath aerosols as a novel sample type for standard clinical diagnosis of respiratory infections
